{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:12:07Z","timestamp":1791497527731,"version":"4.3.4"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.msard.2025.106339","type":"journal-article","created":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T18:22:42Z","timestamp":1740248562000},"page":"106339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Impact of oral Cladribine on paramagnetic rim lesions of Multiple Sclerosis patients"],"prefix":"10.1016","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4142-8375","authenticated-orcid":false,"given":"Mariano","family":"Marrodan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Ya\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael L.","family":"Calandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Agustina","family":"Piedrabuena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda A.","family":"Z\u00e1rate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda C.","family":"Ysrraelit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Fiol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Correale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.msard.2025.106339_bib0001","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1177\/13524585221114750","article-title":"Longitudinal clinical study of patients with iron rim lesions in multiple sclerosis","volume":"28","author":"Altokhis","year":"2022","journal-title":"Mult. Scler."},{"issue":"7878","key":"10.1016\/j.msard.2025.106339_bib0002","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41586-021-03892-7","article-title":"A lymphocyte-microglia-astrocyte axis in chronic active multiple sclerosis","volume":"597","author":"Absinta","year":"2021","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.msard.2025.106339_bib0003","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.3174\/ajnr.A5660","article-title":"Identification of chronic active multiple sclerosis lesions on 3T MRI","volume":"39","author":"Absinta","year":"2018","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"10.1016\/j.msard.2025.106339_bib0004","doi-asserted-by":"crossref","unstructured":"Absinta M, Sati P, Masuzzo F, et al. Association of chronic active Multiple Sclerosis Lesions with Disability In Vivo [published correction appears in JAMA Neurol. 2019 Dec 1;76(12):1520. doi: 10.1001\/jamaneurol.2019.4331]. JAMA Neurol. 2019;76(12):1474-1483. 10.1001\/jamaneurol.2019.2399.","DOI":"10.1001\/jamaneurol.2019.2399"},{"key":"10.1016\/j.msard.2025.106339_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108571","article-title":"2-Chlorodeoxyadenosine (Cladribine) preferentially inhibits the biological activity of microglial cells","volume":"105","author":"Aybar","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.msard.2025.106339_bib0006","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awae013","article-title":"Imaging chronic active lesions in multiple sclerosis: a consensus statement","author":"Bagnato","year":"2024","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.msard.2025.106339_bib0007","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jama.2018.20588","article-title":"Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis","volume":"321","author":"Brown","year":"2019","journal-title":"JAMa"},{"issue":"3","key":"10.1016\/j.msard.2025.106339_bib0009","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.neurad.2020.10.001","article-title":"Brain volumes quantification from MRI in healthy controls: assessing correlation, agreement and robustness of a convolutional neural network-based software against FreeSurfer, CAT12 and FSL","volume":"48","author":"Chaves","year":"2021","journal-title":"J. Neuroradiol."},{"issue":"1","key":"10.1016\/j.msard.2025.106339_bib0010","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ana.25746","article-title":"Longitudinal Assessment of multiple sclerosis with the brain-age paradigm","volume":"88","author":"Cole","year":"2020","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2025.106339_bib0012","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ana.25463","article-title":"Silent progression in disease activity-free relapsing multiple sclerosis","volume":"85","author":"Cree","year":"2019","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106339_bib0013","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00401-016-1636-z","article-title":"Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging","volume":"133","author":"Dal-Bianco","year":"2017","journal-title":"Acta Neuropathol."},{"issue":"3","key":"10.1016\/j.msard.2025.106339_bib0014","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/brain\/awaa436","article-title":"Long-term evolution of multiple sclerosis iron rim lesions in 7 T MRI","volume":"144","author":"Dal-Bianco","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.msard.2025.106339_bib0015","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241306684","article-title":"Chronic active lesions in multiple sclerosis: classification, terminology, and clinical significance","volume":"17","author":"Dal-Bianco","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"2","key":"10.1016\/j.msard.2025.106339_bib0016","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/1352458517690269","article-title":"Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets","volume":"24","author":"De Stefano","year":"2018","journal-title":"Mult. Scler."},{"issue":"14","key":"10.1016\/j.msard.2025.106339_bib0017","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1177\/13524585221106338","article-title":"Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions","volume":"28","author":"Eisele","year":"2022","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2025.106339_bib0018","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1177\/13524585231162262","article-title":"Lesion-level correspondence and longitudinal properties of paramagnetic rim and slowly expanding lesions in multiple sclerosis","volume":"29","author":"Elliott","year":"2023","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2025.106339_bib0019","doi-asserted-by":"crossref","first-page":"741","DOI":"10.32598\/bcn.2023.1324.4","article-title":"Brain MRI volumetric assessment of patients with multiple sclerosis: the volume of basal ganglia, Thalamus, and posterior fossa","volume":"14","author":"Fallah Arzpeyma","year":"2023","journal-title":"Basic Clin. Neurosci."},{"issue":"3","key":"10.1016\/j.msard.2025.106339_bib0020","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3174\/ajnr.A6437","article-title":"SWAN-venule: an optimized MRI technique to detect the Central vein sign in MS plaques","volume":"41","author":"Gait\u00e1n","year":"2020","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"6","key":"10.1016\/j.msard.2025.106339_bib0021","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1177\/13524585231161494","article-title":"Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY\/CLARITY Extension cohort of CLASSIC-MS: an ambispective study","volume":"29","author":"Giovannoni","year":"2023","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2025.106339_bib0022","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/13524585241302170","article-title":"Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: findings for the ORACLE-MS cohort","volume":"31","author":"Giovannoni","year":"2025","journal-title":"Mult. Scler."},{"issue":"12","key":"10.1016\/j.msard.2025.106339_bib0023","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.msard.2025.106339_bib0024","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.msard.2025.106339_bib0025","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1136\/jnnp-2014-307712","article-title":"Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron","volume":"85","author":"Haider","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.msard.2025.106339_bib0027","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/WNF.0b013e318204cd90","article-title":"Cladribine: mode of action and implications for treatment of multiple sclerosis","volume":"34","author":"Leist","year":"2011","journal-title":"Clin. Neuropharmacol."},{"issue":"4","key":"10.1016\/j.msard.2025.106339_bib0028","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00401-018-1818-y","article-title":"Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: a retrospective autopsy cohort analysis","volume":"135","author":"Luchetti","year":"2018","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.msard.2025.106339_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2022.577966","article-title":"Cladribine treatment for highly active multiple sclerosis: real-world clinical outcomes for years 3 and 4","volume":"372","author":"Magalashvili","year":"2022","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2025.106339_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104701","article-title":"B cell depletion therapy does not resolve chronic active multiple sclerosis lesions","volume":"94","author":"Maggi","year":"2023","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.msard.2025.106339_bib0031","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/ana.25877","article-title":"Paramagnetic rim lesions are specific to multiple sclerosis: an international multicenter 3T MRI study","volume":"88","author":"Maggi","year":"2020","journal-title":"Ann. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2025.106339_bib0032","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/14737175.2022.2143265","article-title":"What is the potential of paramagnetic rim lesions as diagnostic indicators in multiple sclerosis?","volume":"22","author":"Martire","year":"2022","journal-title":"Expert. Rev. NeurOther"},{"issue":"9","key":"10.1016\/j.msard.2025.106339_bib0033","article-title":"The prevalence of paramagnetic rim lesions in multiple sclerosis: A systematic review and meta-analysis","volume":"16","author":"Ng","year":"2021","journal-title":"PLoS. One"},{"issue":"10","key":"10.1016\/j.msard.2025.106339_bib0034","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1474-4422(19)30151-6","article-title":"Evangelou N. Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis","volume":"18","author":"Ontaneda","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106339_bib0035","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3389\/fncel.2020.00269","article-title":"Dynamic responses of microglia in animal models of Multiple sclerosis","volume":"14","author":"Plastini","year":"2020","journal-title":"Front. Cell Neurosci."},{"issue":"10","key":"10.1016\/j.msard.2025.106339_bib0036","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000210004","article-title":"Associations between paramagnetic rim lesion evolution and clinical and radiologic disease progression in persons with multiple sclerosis","volume":"103","author":"Reeves","year":"2024","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2025.106339_bib0037","article-title":"Determinants of long-term paramagnetic rim lesion evolution in people with multiple sclerosis","author":"Reeves","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2025.106339_bib0038","doi-asserted-by":"crossref","first-page":"399","DOI":"10.4103\/1673-5374.245330","article-title":"Role of axon resealing in retrograde neuronal death and regeneration after spinal cord injury","volume":"14","author":"Rodemer","year":"2019","journal-title":"Neural Regen. Res."},{"issue":"1","key":"10.1016\/j.msard.2025.106339_bib0040","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00415-023-11969-8","article-title":"Multiple sclerosis: time for early treatment with high-efficacy drugs","volume":"271","author":"Selmaj","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106339_bib0041","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1343531","article-title":"Real-world experience of teriflunomide in relapsing multiple sclerosis: paramagnetic rim lesions may play a role","volume":"15","author":"Tan","year":"2024","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.msard.2025.106339_bib0042","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106339_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.jocn.2024.110810","article-title":"Prognostic significance of paramagnetic rim lesions in multiple sclerosis: A systematic review","volume":"129","author":"Toru Asahina","year":"2024","journal-title":"J. Clin. Neurosci."},{"issue":"1-2","key":"10.1016\/j.msard.2025.106339_bib0044","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jns.2015.07.014","article-title":"The natural history of brain volume loss among patients with multiple sclerosis: a systematic literature review and meta-analysis","volume":"357","author":"Vollmer","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106339_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103340","article-title":"Long-term dynamics of multiple sclerosis iron rim lesions","volume":"57","author":"Weber","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2025.106339_bib0046","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200048","article-title":"Specific patterns of immune cell dynamics may explain the early onset and prolonged efficacy of cladribine tablets: A MAGNIFY-MS substudy","volume":"10","author":"Wiendl","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.msard.2025.106339_bib0047","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1148\/radiol.11110601","article-title":"Chronic multiple sclerosis lesions: characterization with high-field-strength MR imaging","volume":"262","author":"Yao","year":"2012","journal-title":"Radiology."},{"issue":"2","key":"10.1016\/j.msard.2025.106339_bib0048","doi-asserted-by":"crossref","first-page":"e1138","DOI":"10.1212\/NXI.0000000000001138","article-title":"Dimethyl fumarate reduces inflammation in chronic active multiple sclerosis lesions","volume":"9","author":"Zinger","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:40:46Z","timestamp":1762602046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825000823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":44,"alternative-id":["S2211034825000823"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106339","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of oral Cladribine on paramagnetic rim lesions of Multiple Sclerosis patients","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106339","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106339"}}